

18/C.
Goiga
4.903


ATTORNEY'S DOCKET NO: A00752.70001.US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Gregory L. Stahl et al.
Serial No.: 09/464,303
Filed: December 15, 1999
For: METHODS AND PRODUCTS FOR REGULATING LECTIN COMPLEMENT
PATHWAY ASSOCIATED COMPLEMENT ACTIVATION
Examiner: Amy DeCloux
Art Unit: 1644

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Commissioner for Patents, Washington, D.C. 20231, on the 4th day of April, 2003.


Janice A. Vatland

RECEIVED

Commissioner for Patents
Washington, D.C. 20231

APR 14 2003

AMENDMENT

TECH CENTER 1600/2900

Sir:

This amendment is submitted in response to the Office Action mailed from the United States Patent and Trademark Office on October 15, 2002.

In the Claims:

Please amend claim 18 to read as follows:

C
18. (Thrice Amended) A composition, comprising an isolated-binding peptide that—
selectively binds to a human MBL epitope, wherein the isolated MBL binding peptide has an
MBL binding CDR3 region or a functional variant thereof of a monoclonal antibody produced by
a hybridoma cell line selected from the group consisting of hybridoma cell line_(3F8) hybridoma
cell line_(2A9), and hybridoma cell line_(hMBL1.2) deposited under ATCC accession numbers HB-
12621, HB-12620, and HB-12619 respectively, and wherein the functional variant thereof has an
MBL binding CDR3 region with a conservative substitution therein.